Clene Inc.

Clene Inc. (NASDAQ: CLNE) is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of clean-surfaced nanotechnology therapeutics. The company's proprietary electro-crystal-chemistry platform produces catalytically-active nanocrystals comprised of transition elements that possess unique therapeutic properties not present in bulk forms of the same elements. These nanocrystals function as potent catalysts that drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells.

The company's lead drug candidate, CNM-Au8, is a concentrated aqueous suspension of gold nanocrystals in development for treating amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of NAD+, a key metabolite driving ATP energy production. The compound also demonstrates potent antioxidant effects and reduces accumulation of misfolded proteins. Clene has completed a robust portfolio of clinical programs for CNM-Au8, including placebo-controlled trials, open-label extensions, long-term extensions, and expanded access programs, accumulating over 1,100 participant-years of human safety exposure with no serious adverse events identified.

Beyond CNM-Au8, Clene develops additional therapeutic assets including CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent, and CNM-AgZn17, a topical gel formulation for infectious disease and wound healing applications. The company also markets dietary supplements through its wholly-owned subsidiary dOrbital and through an exclusive license with 4Life Research LLC, including products such as rMetx and Gold Factor.

Clene's competitive advantages stem from its proprietary manufacturing processes that produce clean-surfaced, highly faceted nanocrystals with substantially higher catalytic activity and lower toxicity compared to nanoparticles produced using conventional methods. The company's platform demonstrates flexibility and tunability, enabling development of diverse nanocrystal compositions for multiple disease applications. The company maintains a patent-protected position in therapeutic nanotechnology and focuses on addressing high unmet medical needs in central nervous system disorders where traditional small molecule and biologic approaches have proven unsuccessful.